Terms: = Prostate cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Clinical Outcome
1 results:
1. msh2-deficient prostate tumours have a distinct immune response and clinical outcome compared to msh2-deficient colorectal or endometrial cancer.
McCoy P; Mangiola S; Macintyre G; Hutchinson R; Tran B; Pope B; Georgeson P; Hong MKH; Kurganovs N; Lunke S; Clarkson MJ; Cmero M; Kerger M; Stuchbery R; Chow K; Haviv I; Ryan A; Costello AJ; Corcoran NM; Hovens CM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1167-1180. PubMed ID: 34108644
[TBL] [Abstract] [Full Text] [Related]
